Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RXC004 |
Synonyms | |
Therapy Description |
RXC004 inhibits Porcupine (Porcn), thereby inhibits Wnt signaling, potentially resulting in tumor growth inhibition (J Clin Oncol 35, 2017 (suppl; abstr e14094)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RXC004 | RXC-004|RXC 004 | WNT Inhibitor 16 | RXC004 inhibits Porcupine (Porcn), thereby inhibits Wnt signaling, potentially resulting in tumor growth inhibition (J Clin Oncol 35, 2017 (suppl; abstr e14094)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03447470 | Phase I | Nivolumab + RXC004 RXC004 | Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies | Active, not recruiting | GBR | 0 |